MedTrace Logo

Ivermectin/ Permethrin for Scabies

NCT05819983 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-19

No results posted yet for this study

Summary

Scabies is a skin disease characterized by intense itching that worsens at night. It is very contagious, still has a high occurrence rate, and impacts patient quality of life. The use of scabicide followed by a clean and healthy lifestyle is the principle of scabies therapy. The primary treatment option for scabies is permethrin 5% cream. Ivermectin is an alternate treatment for scabies.

Conditions

  • Scabies

Interventions

DRUG

Ivermectin Tablets

Ivermectin 200µg/kg BW

DRUG

Permethrin Cream

Permethrin cream 5%

Sponsors & Collaborators

  • Universitas Padjadjaran

    lead OTHER

Principal Investigators

  • Hendra Gunawan,, M.D., PhD · Faculty of Medicine Universitas Padjadjaran Bandung

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2023-02-01
Completion
2023-03-06

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819983 on ClinicalTrials.gov